Accure Labs Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Accure Labs Private Limited Pharmaceutical Export Portfolio Dataset — 9 Products, $11.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accure Labs Private Limited — Pharmaceutical Exporter Profile (2026) | 9 Products, $11.1M Trade | TransData Nexus

Accure Labs Private Limited

Indian Pharmaceutical Exporter · Oncology Specialist · $11.1M Total Trade · DGFT Verified

Accure Labs Private Limited is an Indian pharmaceutical exporter with a total trade value of $11.1M across 9 products in 2 therapeutic categories. Based on 341 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Gemcitabine ($3.1M), Oxaliplatin ($2.6M), Paclitaxel ($1.6M).

Accure Labs Private Limited — Export Portfolio & Destination Treemap

Accure Labs Private Limited pharmaceutical export portfolio — 9 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Accure Labs Private Limited? — Company Overview & Market Position

Accure Labs Private Limited, established on August 25, 2004, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24232DL2004PTC128617 and is classified as a non-government company. Its authorized capital stands at ₹16.10 crore, with a paid-up capital of ₹0.14 lakh.

The company's primary focus is on the manufacture of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Accure Labs has established a presence in over 18 countries, including regions such as South East Asia, Asia Pacific, Africa, North America, the European Union, the Middle East and North Africa (MENA), Latin America, and the Commonwealth of Independent States (CIS). This extensive international footprint underscores its commitment to global healthcare.

What Does Accure Labs Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Gemcitabine$3.1M 2Oxaliplatin

Product Portfolio — Top 9 by Export Value

Accure Labs Private Limited exports 9 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Gemcitabine	Oncology	$3.1M	107	6.7%	6
2	Oxaliplatin	Advanced Oncology	$2.6M	78	5.5%	4
3	Paclitaxel	Oncology	$1.6M	33	2.0%	7
4	Irinotecan	Oncology	$1.0M	20	2.4%	6
5	Carboplatin	Oncology	$950.0K	19	1.3%	9
6	Temozolomide	Advanced Oncology	$631.0K	45	2.7%	6
7	Imatinib	Advanced Oncology	$629.7K	20	2.2%	7
8	Pemetrexed	Advanced Oncology	$483.0K	15	1.7%	10
9	Thalidomide	Advanced Oncology	$74.5K	4	3.9%	7

Accure Labs Private Limited exports 9 pharmaceutical products across 2 therapeutic categories with a total export value of $11.1M. The top category is Oncology (60.4% of portfolio), followed by Advanced Oncology (39.6%), indicating a concentrated portfolio with the top 5 products accounting for 83.6% of total export value.

Accure Labs Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Accure Labs operates manufacturing facilities in New Delhi and Hyderabad, India. The New Delhi facility is located at Flat No.1406A, 14th Floor, Building No. 89, Hemkunth Chamber, Nehru Place, New Delhi, Delhi 110019. The Hyderabad facility is situated at 18-17/1/F-2, City Home Residency, Road No 3 Kamala Nagar, Hyderabad, Telangana 500060. Both facilities are equipped to produce a range of finished pharmaceutical formulations, catering to diverse therapeutic areas.

3Key Leadership

The leadership team at Accure Labs includes:

Amitabh Ganguli – Director
Sandeep Sharadaprasad Srivastava – Director
Ratan Capoor – Director
Jagrato Roy – Director

These individuals bring a wealth of experience and expertise to the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Accure Labs Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Accure Labs has made significant strides in obtaining regulatory approvals for its products in various international markets. The company has secured approvals from the World Health Organization (WHO) for several of its formulations, facilitating access to markets in Africa, Southeast Asia, and Latin America. Additionally, Accure Labs has obtained European Union Good Manufacturing Practice (EU GMP) certifications, enabling it to export to EU member states. While specific approvals from the U.S. Food and Drug Administration (FDA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) are not publicly disclosed, the company's adherence to international quality standards suggests a commitment to meeting the stringent requirements of these markets.

2Emerging Markets

Accure Labs has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO prequalification of certain products has been instrumental in facilitating market access in these regions, where there is a growing demand for affordable and quality pharmaceutical products. By leveraging its international certifications and adhering to local regulatory standards, Accure Labs continues to strengthen its footprint in these high-growth markets.

3Geographic Strategy

Accure Labs Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

While specific details regarding Accure Labs' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available, the company's adherence to international quality standards and certifications suggests a commitment to meeting the stringent requirements of the U.S. market. Accure Labs' focus on obtaining WHO prequalification and EU GMP certifications indicates a proactive approach to ensuring product quality and regulatory compliance, which are critical for market access in the U.S.

2WHO & EU GMP

Accure Labs has achieved WHO prequalification for certain products, facilitating access to markets in Africa, Southeast Asia, and Latin America. Additionally, the company holds EU GMP certifications, enabling it to export to EU member states. These certifications underscore Accure Labs' commitment to maintaining high manufacturing standards and ensuring product quality across its international markets.

3CDSCO & Indian Regulatory

Accure Labs Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Accure Labs operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not publicly disclosed, the company's focus on oncology products, including Gemcitabine, Oxaliplatin, Paclitaxel, Irinotecan, and Carboplatin, positions it in direct competition with other pharmaceutical companies specializing in cancer treatments. The company's ability to secure regulatory approvals and certifications, such as WHO prequalification and EU GMP, enhances its competitive edge in both domestic and international markets.

2Key Differentiators

Accure Labs' key differentiators include its extensive international presence, with operations in over 18 countries, and its commitment to obtaining international certifications like WHO prequalification and EU GMP. The company's focus on developing and supplying finished pharmaceutical formulations across diverse therapeutic areas, particularly oncology, allows it to cater to a wide range of patient needs. Additionally, Accure Labs' strategic approach to expanding its product portfolio through registrations and launches of novel pharmaceutical products demonstrates its dedication to innovation and market responsiveness.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Accure Labs Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Accure Labs has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $11.1 million USD and 341 shipments across nine products in two therapeutic categories. The company's portfolio concentration, with the top five products accounting for 83.6% of exports, indicates a focused approach to product development and market penetration. The absence of publicly available records indicating regulatory non-compliance further underscores the company's reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Accure Labs as a supplier:

WHO Prequalification: Confirms that the company's products meet international quality standards. Verification can be done through the WHO's official website.

EU GMP Certification: Indicates compliance with European manufacturing standards. Verification can be conducted via the European Medicines Agency (EMA) website.

Frequently Asked Questions — Accure Labs Private Limited

How many pharmaceutical products does Accure Labs Private Limited export from India?

Accure Labs Private Limited exports 9 pharmaceutical products across 2 therapeutic categories. The top exports are Gemcitabine ($3.1M), Oxaliplatin ($2.6M), Paclitaxel ($1.6M), Irinotecan ($1.0M), Carboplatin ($950.0K). Total export value is $11.1M.

What is Accure Labs Private Limited's total pharmaceutical export value?

Accure Labs Private Limited's total pharmaceutical export value is $11.1M, based on 341 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Accure Labs Private Limited cover?

Accure Labs Private Limited exports across 2 therapeutic categories. The largest are Oncology (60.4%, 4 products), Advanced Oncology (39.6%, 5 products).

Get Full Accure Labs Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.